Ticker

PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announced a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute Boston, to evaluate the use of Interna's MNM technology as a delivery enhancer for targeted therapeutic…

SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today announced the advancement to the second phase of its research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego. The decision follows the successful completion of the initial research phase, which was…

NEWTON, Mass.--(BUSINESS WIRE)-- #4DPath--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program.

HAMBURG, Germany & MUNICH--(BUSINESS WIRE)--GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.

DSNKY, LPX and RAL have been added to the Zacks Rank #5 (Strong Sell) List on February 25, 2026.